Pure Global

VAC Regimen for AML Patients Who Failed to Response to VA Regimen - Trial NCT06220162

Access comprehensive clinical trial information for NCT06220162 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital of Soochow University and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06220162
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06220162
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
A Clinical Study of Chidamide in Combination With Venetoclax and Azacitidine (VAC) for Patients With Acute Myeloid Leukemia Who Did Not Achieve CR/CRi/MLFS (PR or NR) With One Cycle of Venetoclax and Azacitidine (VA).

Study Focus

Acute Myeloid Leukemia

chidamide in combination with venetoclax and azacitidine (VAC)

Interventional

drug

Sponsor & Location

The First Affiliated Hospital of Soochow University

Suzhou, China

Timeline & Enrollment

Phase 2

Feb 01, 2024

Dec 01, 2026

32 participants

Primary Outcome

ORR(overall response rate)

Summary

Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve
 remission rate of patients following to VA regimen treatment failure.

ICD-10 Classifications

Myeloid leukaemia
Acute myeloblastic leukaemia [AML]
Myeloid leukaemia, unspecified
Acute myelomonocytic leukaemia
Acute myeloid leukaemia with 11q23-abnormality

Data Source

ClinicalTrials.gov

NCT06220162

Non-Device Trial